KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.51
-0.38 (-2.52%)
As of 2:14PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close14.88
Open15.02
Bid14.49 x 1400
Ask14.51 x 1100
Day's Range14.39 - 15.02
52 Week Range11.01 - 21.42
Volume89,143
Avg. Volume249,878
Market Cap628.693M
Beta (3Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateNov. 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.50
  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 Kura Oncology Inc Earnings Call

  • GlobeNewswire

    Kura Oncology to Present at Stifel Healthcare Conference

    SAN DIEGO, Nov. 12, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting

    SAN DIEGO, Nov. 06, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of.

  • GlobeNewswire

    Kura Oncology Appoints James Basta as Chief Legal Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of James Basta as Chief Legal Officer and Corporate Secretary. Mr. Basta will also serve as the Company’s Chief Compliance Officer. “We are privileged to have an executive of Jim’s caliber join our senior leadership team,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology to Report Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 30, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today reported updated data from a Phase 2 clinical trial of its lead drug candidate, tipifarnib, that show durable anti-tumor activity as a single agent in heavily pretreated patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). As of the October 17, 2019 data cutoff date, a total of 21 HNSCC patients with high HRAS mutant variant allele frequency1 were enrolled in this Phase 2 trial (RUN-HN), of whom 18 were evaluable for efficacy. Ten of the 18 evaluable patients achieved a confirmed partial response (PR), as defined by standard RECIST criteria, for an objective response rate (ORR) of 56% (95% CI 0.31, 0.78).

  • GlobeNewswire

    Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    – Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th – –.

  • GlobeNewswire

    Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    SAN DIEGO, Oct. 16, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology Expands Board of Directors with Appointment of Diane Parks

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of veteran commercial executive Diane Parks to its board of directors. Among her many achievements, Ms. Parks is credited with developing and executing the strategic plan for the launch of the novel CAR-T therapy Yescarta® and the marketing strategies for the blockbuster oncology drug Imbruvica®. “Diane is an accomplished executive with an impressive track record of driving profitable growth for large pharmaceutical and biotech companies,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 1-Aug-19 8:30pm GMT

    Q2 2019 Kura Oncology Inc Earnings Call

  • GlobeNewswire

    Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial of KO-539, the Company’s first-in-class inhibitor of the menin-mixed lineage leukemia (menin-MLL) interaction, in patients with relapsed or refractory acute myeloid leukemia (AML). “We believe KO-539 represents a differentiated approach to the treatment of patients with AML,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced positive topline results from an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory urothelial carcinomas that carry HRAS mutations. The ongoing, single-agent, single-arm trial is designed to enroll at least 18 patients, with a primary endpoint of progression-free survival (PFS) rate at 6 months.

  • GlobeNewswire

    Kura Oncology to Participate in Two Upcoming Investor Conferences

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

  • GlobeNewswire

    Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kathleen Ford as Chief Operating Officer, effective immediately. Ms. Ford replaces John Farnam, who is stepping down from his position to pursue other interests. “We are very fortunate to have recruited an operations veteran with Kathy’s experience to Kura at a time when strategic prioritization and operational execution are among our highest priorities,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology to Present at Wedbush PacGrow Healthcare Conference

    SAN DIEGO, Aug. 07, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • Kura Oncology, Inc. (KURA) 2019 Q2 Earnings Call Transcript
    Motley Fool

    Kura Oncology, Inc. (KURA) 2019 Q2 Earnings Call Transcript

    KURA earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Kura Oncology to Report Second Quarter 2019 Financial Results

    SAN DIEGO, July 25, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s menin-mixed lineage leukemia (menin-MLL) inhibitor KO-539 for the treatment of acute myeloid leukemia (AML). “Orphan Drug Designation for AML represents a significant milestone in the development of KO-539,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the European Patent Office has granted new patents further protecting the Company's lead drug candidate, tipifarnib, a potent and selective farnesyl transferase inhibitor. Tipifarnib is currently being studied in multiple solid tumor and hematologic indications, including a registration-directed clinical trial in HRAS mutant head and neck squamous cell carcinoma (HNSCC).

  • Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue?
    Zacks

    Kura Oncology, Inc. (KURA) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Kura Oncology, Inc. (KURA).

  • Do Insiders Own Shares In Kura Oncology, Inc. (NASDAQ:KURA)?
    Simply Wall St.

    Do Insiders Own Shares In Kura Oncology, Inc. (NASDAQ:KURA)?

    A look at the shareholders of Kura Oncology, Inc. (NASDAQ:KURA) can tell us which group is most powerful. Institutions...

  • What Kind Of Investor Owns Most Of Kura Oncology, Inc. (NASDAQ:KURA)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Kura Oncology, Inc. (NASDAQ:KURA)?

    The big shareholder groups in Kura Oncology, Inc. (NASDAQ:KURA) have power over the company. Insiders often own a...

  • GlobeNewswire

    Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 885,000 shares at the public offering price of $17.00 per share. SVB Leerink and Cowen acted as joint book-running managers for the offering. The securities described above were offered by Kura pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kura with the Securities and Exchange Commission (the “SEC”) and that was declared effective on November 21, 2018.

  • GlobeNewswire

    Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a price to the public of $17.00 per share.  Kura has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of its common stock. The gross proceeds to Kura from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be $100.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Kura. SVB Leerink and Cowen are acting as joint book-running managers for the offering.  Wedbush PacGrow and Oppenheimer & Co. are acting as co-lead managers, and H.C. Wainwright & Co. is acting as co-manager for the offering.